Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Trial Identifier:	3475-204
Sponsor:	MSD
Start Date:	May 2016
Primary Completion Date:	January 2026
Study Completion Date:	January 2026
Condition:	Hodgkin's lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Protocol Plain Language Summary-English

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.